I. Hennig

1.5k total citations
31 papers, 970 citations indexed

About

I. Hennig is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, I. Hennig has authored 31 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in I. Hennig's work include Viral-associated cancers and disorders (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Soft tissue tumor case studies (4 papers). I. Hennig is often cited by papers focused on Viral-associated cancers and disorders (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Soft tissue tumor case studies (4 papers). I. Hennig collaborates with scholars based in United Kingdom, Switzerland and United States. I. Hennig's co-authors include Jean A. Laissue, Jean–Claude Reubi, Bettina Borisch, Cris S. Constantinescu, Jonathan C.M. Wong, Pavel Gershkovich, David A. Barrett, Jong Bong Lee, Atheer Zgair and Peter M. Fischer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

I. Hennig

30 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Hennig United Kingdom 16 354 247 198 197 180 31 970
Roberta Lotti Italy 18 166 0.5× 229 0.9× 159 0.8× 83 0.4× 313 1.7× 55 1.1k
Şeyda Erdoğan Türkiye 16 190 0.5× 108 0.4× 79 0.4× 125 0.6× 173 1.0× 57 757
Ji‐Chen Ho Taiwan 15 70 0.2× 194 0.8× 182 0.9× 53 0.3× 108 0.6× 41 909
M. Saint‐Jean France 21 355 1.0× 74 0.3× 40 0.2× 121 0.6× 310 1.7× 62 1.3k
Kazuhide Ochi Japan 15 56 0.2× 293 1.2× 101 0.5× 85 0.4× 188 1.0× 54 1.1k
Leonidas Manolopoulos Greece 18 357 1.0× 91 0.4× 114 0.6× 289 1.5× 300 1.7× 61 1.4k
Andreas D. Rink Germany 14 231 0.7× 62 0.3× 86 0.4× 148 0.8× 302 1.7× 44 1.2k
Domenico Adorno Italy 20 327 0.9× 118 0.5× 43 0.2× 41 0.2× 162 0.9× 48 1.1k
Mohammed Imran Khan United States 18 234 0.7× 72 0.3× 75 0.4× 139 0.7× 304 1.7× 47 807
Pietro Cappugi Italy 19 127 0.4× 127 0.5× 54 0.3× 137 0.7× 122 0.7× 49 879

Countries citing papers authored by I. Hennig

Since Specialization
Citations

This map shows the geographic impact of I. Hennig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Hennig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Hennig more than expected).

Fields of papers citing papers by I. Hennig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Hennig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Hennig. The network helps show where I. Hennig may publish in the future.

Co-authorship network of co-authors of I. Hennig

This figure shows the co-authorship network connecting the top 25 collaborators of I. Hennig. A scholar is included among the top collaborators of I. Hennig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Hennig. I. Hennig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hennig, I., et al.. (2021). Immune checkpoint inhibitors: current status. BMJ Supportive & Palliative Care. 14(e2). e1678–e1683. 5 indexed citations
2.
Kasbekar, Anand V., et al.. (2021). Imbalance Associated With Cisplatin Chemotherapy in Adult Cancer Survivors: A Clinical Study. Otology & Neurotology. 42(6). e730–e734. 6 indexed citations
3.
4.
Bayly, Joanne, Nicola Peat, Geoffrey Warwick, et al.. (2018). Developing an integrated rehabilitation model for thoracic cancer services: views of patients, informal carers and clinicians. Pilot and Feasibility Studies. 4(1). 160–160. 15 indexed citations
5.
McKenzie, Hayley, Graham M. Mead, Robert Huddart, et al.. (2018). Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. Clinical Genitourinary Cancer. 16(6). 458–465.e2. 2 indexed citations
6.
Zgair, Atheer, Jong Bong Lee, Jonathan C.M. Wong, et al.. (2017). Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Scientific Reports. 7(1). 14542–14542. 98 indexed citations
7.
Crosby, Vincent, et al.. (2016). Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. Lung Cancer. 104. 75–78. 3 indexed citations
8.
Eastley, Nicholas, Thomas A. McCulloch, C. Esler, et al.. (2016). Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. European Journal of Surgical Oncology. 42(7). 1071–1083. 56 indexed citations
9.
Crosby, Vincent, Vanessa Potter, I. Hennig, et al.. (2016). Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study. Supportive Care in Cancer. 25(4). 1257–1261. 13 indexed citations
10.
Eastley, Nicholas, I. Hennig, C. Esler, & Robert U. Ashford. (2015). Nationwide Trends in the Current Management of Desmoid (Aggressive) Fibromatosis. Clinical Oncology. 27(6). 362–368. 21 indexed citations
11.
12.
13.
Keus, Ronald B., Remi A. Nout, Jean‐Yves Blay, et al.. (2013). Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998). Annals of Oncology. 24(10). 2672–2676. 105 indexed citations
14.
Harvey, Tracey J., I. Hennig, Steven D. Shnyder, et al.. (2011). Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. Cancer Gene Therapy. 18(11). 773–784. 16 indexed citations
15.
Jevremović, Dragan, Rajiv Gulati, I. Hennig, et al.. (2004). Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. American Journal of Physiology-Heart and Circulatory Physiology. 287(2). H494–H500. 46 indexed citations
16.
Roos, Jessica, I. Hennig, J Schwaller, et al.. (2001). Expression of <i>TCL1</i> in Hematologic Disorders. Pathobiology. 69(2). 59–66. 13 indexed citations
17.
Mazzucchelli, Luca, et al.. (1996). Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers. Gastroenterology. 110(6). 1719–1726. 36 indexed citations
18.
Hennig, I., et al.. (1995). Substance‐P receptors in human primary neoplasms: Tumoral and vascular localization. International Journal of Cancer. 61(6). 786–792. 173 indexed citations
19.
Borisch, Bettina, I. Hennig, Fritz Horber, Kurt Bürki, & Jean A. Laissue. (1992). Enteropathy-associated T-cell lymphoma in a renal transplant patient with evidence of Epstein-Barr virus involvement. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 421(5). 443–447. 26 indexed citations
20.
Borisch, Bettina, Jürgen Finke, I. Hennig, et al.. (1992). Distribution and localization of Epstein–Barr virus subtypes A and B in AIDS‐related lymphomas and lymphatic tissue of HIV‐positive patients. The Journal of Pathology. 168(2). 229–236. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta Lotti Breakdown of academic impact, for papers by Şeyda Erdoğan Breakdown of academic impact, for papers by Ji‐Chen Ho Breakdown of academic impact, for papers by M. Saint‐Jean Breakdown of academic impact, for papers by Kazuhide Ochi Breakdown of academic impact, for papers by Leonidas Manolopoulos Breakdown of academic impact, for papers by Andreas D. Rink Breakdown of academic impact, for papers by Domenico Adorno Breakdown of academic impact, for papers by Mohammed Imran Khan Breakdown of academic impact, for papers by Pietro Cappugi
Rankless by CCL
2026